Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Jeffrey S. Heier, MD"'
Autor:
Lars-Olof Hattenbach, MD, PhD, Francis Abreu, PhD, Pablo Arrisi, PhD, Karen Basu, PhD, Carl J. Danzig, MD, Robyn Guymer, MD, PhD, Zdenka Haskova, MD, PhD, Jeffrey S. Heier, MD, Aachal Kotecha, PhD, Ying Liu, PhD, Anat Loewenstein, MD, András Seres, MD, Jeffrey R. Willis, MD, PhD, Charles C. Wykoff, MD, PhD, Liliana P. Paris, MD, PhD
Publikováno v:
Ophthalmology Science, Vol 3, Iss 3, Pp 100302- (2023)
Purpose: Dual inhibition of angiopoietin-2 and VEGF-A with faricimab (Vabysmo) offers excellent visual acuity gains with strong durability in patients with diabetic macular edema (ME) and neovascular age-related macular degeneration. The phase III BA
Externí odkaz:
https://doaj.org/article/868cf61b8f6b4378aa110bd7320825d8
Autor:
Arshad M. Khanani, MD, MA, Robyn H. Guymer, MD, PhD, Karen Basu, PhD, Heather Boston, MSc, Jeffrey S. Heier, MD, Jean-François Korobelnik, MD, Aachal Kotecha, PhD, Hugh Lin, MD, MBA, David Silverman, MBChB, MRCOphth, Balakumar Swaminathan, MSc, Jeffrey R. Willis, MD, PhD, Young Hee Yoon, MD, PhD, Carlos Quezada-Ruiz, MD
Publikováno v:
Ophthalmology Science, Vol 1, Iss 4, Pp 100076- (2021)
Purpose: To describe the design and rationale of the phase 3 TENAYA (ClinicalTrials.gov identifier, NCT03823287) and LUCERNE (ClinicalTrials.gov identifier, NCT03823300) trials that aimed to assess efficacy, safety, and durability of faricimab, the f
Externí odkaz:
https://doaj.org/article/4e1a35a48b634c0c9a19648d30c76ede